Despite no recorded outbreak of cervical cancer nor change in sexual behavioral risks among teenagers, Gardasil vaccine was studied for less than two years prior to its approval. This was particularly curious since the cancer the vaccine purports to prevent does not present itself for 20-30 years. And, while the drug was tested only on women aged 16-23 before it became the first licensed HPV vaccine in the United States, today it is recommended for boys and girls as young as 10 years old. Moreover, Gardasil was not tested on people with health problems nor in combination with all the other vaccines routinely administered to American adolescents, such as Tdap and meningococcal vaccines. Contrary to the ad campaign created by Merck that depicts tragic-looking teenagers asking their parents why they weren’t protected from getting cancer, there have been no reports of any teen contracting cervical cancer from HPV ever.
A new study was published earlier this month (July 2017) in the journal Clinical Rheumatology looking at serious adverse events after HPV vaccination. The title of the study is: Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series. This is an international peer-reviewed journal that has been around since 1945. It is the "Journal of the International League of Associations for Rheumatology," and is the official journal of the Belgian Rheumatology Society. The study was conducted by doctors from the Rheumatology Department and the Immunology Department at the National Institute of Cardiology in Mexico City. The results of their study found: 1. The lack of inert placebo in the vast majority of prelicensure HPV vaccine randomized studies, 2. Large randomized trials disclosed significantly more severe adverse events in the tested HPV vaccine cohort, 3. Pooled safety analysis found more post-immunization symptoms in bivalent HPV vaccine vs. hepatitis A vaccine, 4. Post-marketing HPV vaccine adverse events case series describe similar cluster of symptoms than those reported in pre-clinical trials, 5. The European Medicines Agency report on HPV vaccine safety looked at specific diagnoses and not at symptoms clusters, 6. In-depth analysis of some supportive post-marketing HPV vaccine safety studies discloses disquieting findings. The study found the statistics regarding the new Gardasil 9 particularly troubling, as the statistics suggest that severe harm is suffered every 140 injections, and the number needed to vaccinate in order to see any perceived benefits to the vaccine is 1757. Such a critical study of any vaccine would probably never get published in the United States, as it is considered professional suicide to criticize the extremist position that all vaccines are safe and effective, and that the "science is settled" regarding vaccines.
The FDA has just approved the use of a reportedly "new and improved" version of Gardasil, which will be marketed as Gardasil 9. According to the FDA approval letter, this action was taken without consultation with VRBPAC (the Vaccines and Related Biological Products Advisory Committee) which is responsible for reviewing and evaluating data concerning the safety, effectiveness, and appropriate use of vaccines and related biological products. A reading of the package insert for the new Gardasil vaccine reveals that Gardasil 9 has more than DOUBLE the amount of toxic aluminum, increased auto immune disorders and fetal deaths among pregnant women during drug trials, and recorded a rate of 2,300 serious adverse events to try and prevent 7.9 cases of cervical cancer. Will you or your children be getting the "new and improved" HPV Gardasil vaccine?